Rani Therapeutics, LLC
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2010-01-01
- Employees
- -
- Market Cap
- $181.4M
- Website
- http://rcub.ac.in/
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
An Early Phase Study of RT-114
- Conditions
- Obesity
- Interventions
- Combination Product: RT-114 is the RaniPill capsule with PG-102 for the treatment of obesityOther: Placebo
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- RANI Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT06891287
Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- RANI Therapeutics
- Target Recruit Count
- 55
- Registration Number
- NCT05890118
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- RANI Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT05164614
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
Pill Swallow Study
- Conditions
- Not Determined
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- RANI Therapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT04911296
- Locations
- 🇺🇸
Clinical Trials of Texas, San Antonio, Texas, United States
A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform
- Conditions
- Healthy Volunteers
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- RANI Therapeutics
- Target Recruit Count
- 62
- Registration Number
- NCT03798912
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
News
Rani Therapeutics and Chugai Pharmaceutical Partner to Advance Oral Antibody Delivery Technology
Rani Therapeutics has entered a research agreement with Chugai Pharmaceutical to evaluate the application of its RaniPill® oral delivery technology for Chugai's antibodies against undisclosed targets.
Rani Therapeutics Achieves Bioequivalence with Oral GLP-1/GLP-2 Dual Agonist for Obesity Treatment
Rani Therapeutics demonstrated that RT-114, an oral GLP-1/GLP-2 dual agonist delivered via RaniPill® capsule, achieved 111% bioavailability compared to subcutaneous injection in preclinical studies, with comparable weight loss outcomes.